Compare Emerson Electric Co. (EMR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Zimmer Biomet Holdings Inc — how do they compare? Emerson Electric Co. trades at $162.23 (market cap $88.72B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Emerson Electric Co. is far larger — about 5.2× Zimmer Biomet Holdings Inc's market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EMR | ZBH | |
|---|---|---|
Market Cap | $88.72B | $16.95B |
Volume | 2,355,255 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $164.38 | $103.98 |
52-Week Low | $123.30 | $79.58 |
Typical Hold Time | 81 Days | 89 Days |
Enterprise Value | $99.80B | $24.02B |
Dividend Yield | 1.4% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.83, up 1.64% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 13.83% net income margin and a 12.81% ROE. Revenue is projected to grow to $18.6B in 2026, and the company maintains a solid balance sheet with $3.59B in cash. Analysts are largely positive, with a consensus price target of $165.90.
EMR presents a favorable outlook with upward earnings momentum and analyst support, though valuation multiples like a P/E of 34.81 suggest premium pricing. Risks include competitive pressures and macroeconomic volatility. The stock remains a candidate for growth-oriented investors seeking industrial sector exposure.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
